A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.

Triangle Pharmaceuticals11 sites in 5 countries30 target enrollmentAugust 2002

ConditionsHepatitis B

Drugsclevudine (drug)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Hepatitis B
Sponsor: Triangle Pharmaceuticals
Enrollment: 30
Locations: 11
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.

Registry

clinicaltrials.gov

Start Date

August 2002

End Date

TBD

Last Updated

20 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Triangle Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

•HBV DNA positive with DNA levels at screening greater than or equal to 3,000,000 copies/mL.
•Documented to be HBsAg positive for \> 6 months OR HBsAg positive and IgM anti-HBc negative and anti-HBs negative. Patients may be HBeAg positive, and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive.
•HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive with positive HBsAg for the previous 6 months
•AST and ALT levels which are less than or equal to 10 times the upper limit of normal.
•Bilirubin levels less than or equal to 1.5 x ULN or bilirubin levels \> 1.5 x ULN with diagnosis of Gilbert's disease and conjugated bilirubin within normal limits.

Exclusion Criteria

•Currently receiving antiviral, immunomodulatory or corticosteroid therapy
•Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection
•Previous treatment with interferon must have ended at least 6 months prior to screening visit
•History of ascites, variceal hemorrhage or hepatic encephalopathy
•Co-infection with HCV or HIV
•Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein)